JP2006516949A5 - - Google Patents

Download PDF

Info

Publication number
JP2006516949A5
JP2006516949A5 JP2004536551A JP2004536551A JP2006516949A5 JP 2006516949 A5 JP2006516949 A5 JP 2006516949A5 JP 2004536551 A JP2004536551 A JP 2004536551A JP 2004536551 A JP2004536551 A JP 2004536551A JP 2006516949 A5 JP2006516949 A5 JP 2006516949A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
pharmaceutical composition
methionine
alkyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004536551A
Other languages
English (en)
Japanese (ja)
Other versions
JP4173861B2 (ja
JP2006516949A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/029017 external-priority patent/WO2004024095A2/en
Publication of JP2006516949A publication Critical patent/JP2006516949A/ja
Publication of JP2006516949A5 publication Critical patent/JP2006516949A5/ja
Application granted granted Critical
Publication of JP4173861B2 publication Critical patent/JP4173861B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004536551A 2002-09-13 2003-09-15 耐性HBV菌株の治療のためのβ−L−2’−デオキシヌクレオシド及び併用療法 Expired - Fee Related JP4173861B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41067502P 2002-09-13 2002-09-13
PCT/US2003/029017 WO2004024095A2 (en) 2002-09-13 2003-09-15 ß-L-2'-DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008099992A Division JP2008273960A (ja) 2002-09-13 2008-04-08 耐性HBV菌株の治療のためのβ−L−2’−デオキシヌクレオシド及び併用療法

Publications (3)

Publication Number Publication Date
JP2006516949A JP2006516949A (ja) 2006-07-13
JP2006516949A5 true JP2006516949A5 (cg-RX-API-DMAC7.html) 2006-11-02
JP4173861B2 JP4173861B2 (ja) 2008-10-29

Family

ID=31994179

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004536551A Expired - Fee Related JP4173861B2 (ja) 2002-09-13 2003-09-15 耐性HBV菌株の治療のためのβ−L−2’−デオキシヌクレオシド及び併用療法
JP2008099992A Pending JP2008273960A (ja) 2002-09-13 2008-04-08 耐性HBV菌株の治療のためのβ−L−2’−デオキシヌクレオシド及び併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008099992A Pending JP2008273960A (ja) 2002-09-13 2008-04-08 耐性HBV菌株の治療のためのβ−L−2’−デオキシヌクレオシド及び併用療法

Country Status (14)

Country Link
US (3) US7186700B2 (cg-RX-API-DMAC7.html)
EP (1) EP1572095B1 (cg-RX-API-DMAC7.html)
JP (2) JP4173861B2 (cg-RX-API-DMAC7.html)
KR (2) KR100855907B1 (cg-RX-API-DMAC7.html)
CN (1) CN100536853C (cg-RX-API-DMAC7.html)
AU (1) AU2003278816A1 (cg-RX-API-DMAC7.html)
BR (1) BR0314259A (cg-RX-API-DMAC7.html)
CA (1) CA2498731C (cg-RX-API-DMAC7.html)
DK (1) DK1572095T3 (cg-RX-API-DMAC7.html)
ES (1) ES2547002T3 (cg-RX-API-DMAC7.html)
HU (1) HUE027522T2 (cg-RX-API-DMAC7.html)
PT (1) PT1572095E (cg-RX-API-DMAC7.html)
SI (1) SI1572095T1 (cg-RX-API-DMAC7.html)
WO (1) WO2004024095A2 (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
WO2001022972A2 (en) * 1999-09-25 2001-04-05 University Of Iowa Research Foundation Immunostimulatory nucleic acids
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
SI1572095T1 (sl) * 2002-09-13 2015-12-31 Novartis Ag Beta-l-2'-deoksinukleozidi za uporabo pri zdravljenju odpornih sevov hbv
EP1608403A2 (en) * 2003-04-02 2005-12-28 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
RU2358979C2 (ru) * 2003-05-30 2009-06-20 Фармассет, Инк. Модифицированные фторированные аналоги нуклеозида
US20070167353A1 (en) * 2003-10-24 2007-07-19 John Hilfinger Prodrug composition
CN101023094B (zh) * 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
ES2725457T3 (es) 2004-09-14 2019-09-24 Gilead Pharmasset Llc Preparación de ribofuranosil pirimidinas y purinas 2'fluoro-2'-alquil-sustituidas u otras opcionalmente sustituidas y sus derivados
KR20070110901A (ko) 2005-03-04 2007-11-20 다이나박스 테크놀로지 코퍼레이션 항원에 콘쥬게이트되고 버퍼 조건 및 추가의 부형제들에의해 안정화된 면역자극성 서열(iss)을 갖는올리고뉴클레오티드를 포함하는 백신
RU2008109649A (ru) * 2005-08-15 2009-09-27 Ф.Хоффманн-Ля Рош Аг (Ch) ПЭГ-IFNα И РИБАВИРИН ДЛЯ ЛЕЧЕНИЯ ВИРУСА ГЕПАТИТА В
JP2010513484A (ja) * 2006-12-20 2010-04-30 メルク・シャープ・エンド・ドーム・コーポレイション Rna依存性rnaウイルス感染治療用ヌクレオシド環状ホスホロアミデート
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
WO2008106166A2 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Methods for the treatment of liver diseases using specified matrix metalloproteinase (mmp) inhibitors
US7964580B2 (en) * 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US20090082306A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched telbivudine
US8173621B2 (en) * 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
AR074897A1 (es) 2008-12-23 2011-02-23 Pharmasset Inc Fosforamidatos de nucleosidos
MX2011006890A (es) 2008-12-23 2011-07-20 Pharmasset Inc Analogos de nucleosidos.
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
AP2012006535A0 (en) 2010-03-31 2012-10-31 Gilead Pharmasset Llc Stereoselective synthesis of phosphorous containing actives
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
ES2716158T3 (es) 2010-11-30 2019-06-10 Gilead Pharmasset Llc 2'-spiro-nucleótidos para el tratamiento de hepatitis C
CN102140534A (zh) * 2010-12-15 2011-08-03 深圳华大基因科技有限公司 一种hbv基因的核苷酸突变位点的检测方法
SI3505528T1 (sl) 2011-04-21 2021-04-30 Glaxo Group Limited Modulacija izražanja virusa hepatitisa B (HBV)
HRP20180237T4 (hr) 2011-09-16 2020-12-11 Gilead Pharmasset Llc Metode za liječenje hcv-a
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CA2869554A1 (en) * 2012-04-04 2013-10-10 Duke University Methods of using cerium oxide nanoparticles to mitigate or protect against radiation injury
EP2950786B1 (en) 2013-01-31 2019-11-27 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
US9688666B2 (en) * 2013-02-07 2017-06-27 Tobira Therapeutics, Inc. Lamivudine salts
EA201690473A1 (ru) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Комбинированный состав двух противовирусных соединений
WO2018092728A1 (ja) 2016-11-16 2018-05-24 国立研究開発法人国立国際医療研究センター 抗ウイルス活性等の生理活性を有するヌクレオシド誘導体
EP3596202A4 (en) 2017-03-14 2021-01-27 The Regents of the University of California GENOME-WIDE IDENTIFICATION OF IMMUNEVASIONAL FUNCTIONS IN A VIRUS
US11446303B2 (en) 2019-06-21 2022-09-20 Tosk, Inc. Uridine phosphorylase (UPase) inhibitors for treatment of liver conditions
WO2022010778A1 (en) 2020-07-07 2022-01-13 Tosk, Inc. Uridine phosphorylase inhibitors to treat or prevent pulmonary disease
CN115607532A (zh) * 2021-07-15 2023-01-17 上海市公共卫生临床中心 大黄酸在制备改善老年机体免疫功能药物中的应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US4916122A (en) * 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
US5190926A (en) * 1987-01-28 1993-03-02 University Of Georgia Research Foundation, Inc. 3'-azido-2',3'-dideoxypyrimidines and related compounds as antiviral agents
GB8719367D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
JPH03501253A (ja) 1987-09-22 1991-03-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア エイズ(aids)治療を目的とするリポソームによるヌクレオシド類似物質
EP0355131B1 (en) 1987-10-28 1996-09-04 Pro-Neuron, Inc. Acyl deoxyribonucleoside derivatives and uses thereof
US6020322A (en) * 1993-11-09 2000-02-01 Pro-Neuron, Inc. Acyl deoxyribonucleoside derivatives and uses thereof
SE8802687D0 (sv) 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5194654A (en) * 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5463092A (en) * 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
AU7872491A (en) 1990-05-07 1991-11-27 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
EP0531452A4 (en) 1990-05-29 1993-06-09 Vical, Inc. Synthesis of glycerol di- and triphosphate derivatives
ES2083580T3 (es) 1990-06-13 1996-04-16 Arnold Glazier Profarmacos de fosforo.
US5256641A (en) * 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5543389A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
IT1246983B (it) 1990-11-13 1994-12-12 Consiglio Nazionale Ricerche L-2'-desossiuridine e composizioni farmaceutiche che le contengono.
IL100502A (en) 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
CA2105486C (en) 1991-03-06 2003-10-28 George Robert Painter Iii Therapeutic nucleosides
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
CA2112803A1 (en) 1991-07-12 1993-01-21 Karl Y. Hostetler Antiviral liponucleosides: treatment of hepatitis b
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
EP0691981A1 (en) 1993-03-10 1996-01-17 The Wellcome Foundation Limited Tumor targeting with l-enantiomeric oligonucleotide conjugates of immunoreagents and of chelated radionuclides
JP3693357B2 (ja) 1993-04-09 2005-09-07 峯郎 実吉 逆転写酵素阻害剤
JPH08510236A (ja) 1993-05-12 1996-10-29 カール ワイ. ホステトラー 局所使用のためのアシクロビル誘導体
AU7954694A (en) 1993-09-10 1995-03-27 Centre National De La Recherche Scientifique (Cnrs) Nucleosides with anti-hepatitis b virus activity
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
WO1996011204A1 (de) 1994-10-07 1996-04-18 Max-Delbrück-Centrum für Molekulare Medizin NEUE β-L-NUCLEOSIDE UND IHRE VERWENDUNG
US5559101A (en) * 1994-10-24 1996-09-24 Genencor International, Inc. L-ribofuranosyl nucleosides
US5696277A (en) 1994-11-15 1997-12-09 Karl Y. Hostetler Antiviral prodrugs
ES2276404T3 (es) 1995-06-07 2007-06-16 Emory University Nucleosidos con actividad antivirus de la hepatitis-b.
AT409815B (de) 1995-07-11 2002-11-25 Enco En Componenten Ges M B H Anlage zur aufbereitung biogener rohstoffe
US6025335A (en) * 1995-09-21 2000-02-15 Lipitek International, Inc. L-Nucleoside Dimer Compounds and therapeutic uses
US6242187B1 (en) * 1996-01-29 2001-06-05 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US6194391B1 (en) * 1998-06-24 2001-02-27 Emory University 3′-azido-2′,3′-dideoxyuridine administration to treat HIV and related test protocol
JP3959176B2 (ja) 1998-06-25 2007-08-15 松下電器産業株式会社 ファンモータ駆動装置
US6444652B1 (en) * 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
US6395716B1 (en) 1998-08-10 2002-05-28 Novirio Pharmaceuticals Limited β-L-2′-deoxy-nucleosides for the treatment of hepatitis B
US6065181A (en) * 1998-09-03 2000-05-23 Cleveland; Thomas Portable ticket scratching device with vacuum
AR028149A1 (es) 1999-07-08 2003-04-30 Innogenetics Nv Deteccion de la resistencia a los farmacos contra la hepatitis b
US6265181B1 (en) 1999-09-24 2001-07-24 The Public Health Research Institute Of The City Of New York, Inc. Dosing and development of antimicrobial and antiviral drugs determined by restriction of resistant mutant selection
DE60105424T2 (de) * 2000-05-26 2005-09-22 Idenix (Cayman) Ltd. Methoden zur behandlung von delta hepatitis virus infektionen mit beta-l-2' deoxy-nucleosiden
MY141594A (en) 2000-06-15 2010-05-14 Novirio Pharmaceuticals Ltd 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
US6875751B2 (en) * 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
AU2001269092A1 (en) * 2000-06-27 2002-01-08 Axxima Pharmaceuticals Ag Inhibitors of hepatitis b virus infection
US6855346B2 (en) * 2001-10-05 2005-02-15 Tzu-Sheng Wu Pharmaceutical composition having prophylactic effects on lamivudine-related disease relapse and drug resistance and methods of using the same
SI1572095T1 (sl) * 2002-09-13 2015-12-31 Novartis Ag Beta-l-2'-deoksinukleozidi za uporabo pri zdravljenju odpornih sevov hbv

Similar Documents

Publication Publication Date Title
CA2498731A1 (en) .beta.-l-2'-deoxynucleosides for the treatment of resistant hbv strains and combination therapies
US8895531B2 (en) 2′-fluoronucleoside phosphonates as antiviral agents
JP2004513070A5 (cg-RX-API-DMAC7.html)
CN1257912C (zh) 用于治疗乙型肝炎的β-L-2′-脱氧-核苷
Mahmoud et al. Antiviral nucleoside and nucleotide analogs: a review
KR101508018B1 (ko) 바이러스 감염의 치료를 위한 화합물 및 제약 조성물
CN1195526C (zh) 含对映体纯β-D-二氧戊环核苷的药物产品
JP6860585B2 (ja) 非環状抗ウイルス 優先出願の参照による組み込み
CN1444483A (zh) 用β-L-2′-脱氧核苷治疗丁型肝炎病毒感染的方法
WO2014124430A1 (en) Nucleotide and nucleoside therapeutic compositions and uses related thereto
US20050119286A1 (en) Beta-2'-or 3'-halonucleosides
JP2005503358A5 (cg-RX-API-DMAC7.html)
JP2004533401A5 (cg-RX-API-DMAC7.html)
CA2904692A1 (en) Modified 4'-nucleosides as antiviral agents
EA020244B1 (ru) Урацильные циклопропилнуклеотиды
WO1996022778A1 (en) Derivatives of succinamide and their use as metalloproteinase inhibitor
CN1296011A (zh) 嘌呤l-核苷、其类似物及其用途
RU2005118421A (ru) 2'-разветвленные нуклеозиды и мутация flaviviridae
JP2011246469A (ja) B型肝炎ウイルス活性を持ったヌクレオシド
JP2008255121A (ja) 抗b型肝炎ウイルス活性を有するヌクレオシド
CZ2003122A3 (cs) 3´-Substituované-beta-L-nukleosidy
WO2009085267A1 (en) Antiviral compounds
CN1812995A (zh) 工业化规模的核苷合成
CN101031308A (zh) 由rna依赖性dna聚合酶活化的药物前体
WO2020121122A1 (en) Cyclobutyl nucleoside analogs as anti-virals